Literature DB >> 33179863

The state of renal sympathetic denervation for the management of patients with hypertension: A systematic review and meta-analysis.

Moinuddin Syed1, Mohammed Osman1, Hani Alhamoud1, Maryam Saleem1, Muhamad Bilal Munir1,2, Babikir Kheiri3, Sudarshan Balla1, Akram Kawsara1, Ramesh Daggubati1.   

Abstract

BACKGROUND: Sympathetic nervous system plays a central role in the development and persistence of essential hypertension. In recent years renal sympathetic denervation (RSD) has emerged as a promising option for the treatment of patients with hypertension.
METHODS: We conducted a literature search of PubMed, EMBASE, Cochrane library and Clinicaltrials.gov from inception through April 20, 2020. Outcomes of interest were change in 24-hour ambulatory systolic (ASBP) or diastolic blood pressure (ADBP) and change in office systolic (OSBP) or diastolic blood pressure (ODBP). We pooled data from randomized controlled trials (RCTS) comparing RSD to sham procedures in the management of hypertension using the random effect model.
RESULTS: A total of 1,363 patients from eight studies were included in the current meta-analysis. The mean age of the included patients was 56 ± 2.6 years, 29% were women and the median duration of maximum follow up was 6-month (range 3-12 month). There was more reduction favoring RSD in ASBP (Weighted mean difference [WMD] -3.55; 95% CI -4.91 - -2.19, p < .001, I2 = 0%), ADBP (WMD -1.87; 95% CI -3.07 - -0.66, p = .002, I2 = 43%), OSBP (WMD -5.5; 95% CI -7.59 - -3.40, p < .001, I2 = 7%) and ODBP (WMD -3.20; 95% CI -4.47 - -1.94, p < .001, I2 = 14%).
CONCLUSION: The use of RSD for the management of hypertension resulted in effective reduction in the ambulatory and office blood pressure compared to sham procedure. Adequately powered RCTs of RSD are needed to confirm safety, reproducibility and assess the impact on clinical outcomes.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  hypertension; renal sympathetic denervation; resistant hypertension

Mesh:

Year:  2020        PMID: 33179863      PMCID: PMC8381272          DOI: 10.1002/ccd.29384

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  23 in total

Review 1.  Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings.

Authors:  Murray Esler
Journal:  J Am Soc Hypertens       Date:  2014-06-12

2.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

3.  Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial.

Authors:  Michel Azizi; Roland E Schmieder; Felix Mahfoud; Michael A Weber; Joost Daemen; Justin Davies; Jan Basile; Ajay J Kirtane; Yale Wang; Melvin D Lobo; Manish Saxena; Lida Feyz; Florian Rader; Philipp Lurz; Jeremy Sayer; Marc Sapoval; Terry Levy; Kintur Sanghvi; Josephine Abraham; Andrew S P Sharp; Naomi D L Fisher; Michael J Bloch; Helen Reeve-Stoffer; Leslie Coleman; Christopher Mullin; Laura Mauri
Journal:  Lancet       Date:  2018-05-23       Impact factor: 79.321

Review 4.  Sympathetic nervous system and the kidney in hypertension.

Authors:  Gerald F DiBona
Journal:  Curr Opin Nephrol Hypertens       Date:  2002-03       Impact factor: 2.894

5.  Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation.

Authors:  Markus P Schlaich; Elisabeth Lambert; David M Kaye; Zygmunt Krozowski; Duncan J Campbell; Gavin Lambert; Jacqui Hastings; Anuradha Aggarwal; Murray D Esler
Journal:  Hypertension       Date:  2003-11-10       Impact factor: 10.190

6.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

Authors:  Jackson T Wright; Jeff D Williamson; Paul K Whelton; Joni K Snyder; Kaycee M Sink; Michael V Rocco; David M Reboussin; Mahboob Rahman; Suzanne Oparil; Cora E Lewis; Paul L Kimmel; Karen C Johnson; David C Goff; Lawrence J Fine; Jeffrey A Cutler; William C Cushman; Alfred K Cheung; Walter T Ambrosius
Journal:  N Engl J Med       Date:  2015-11-09       Impact factor: 91.245

7.  Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial.

Authors:  Michael Böhm; Kazuomi Kario; David E Kandzari; Felix Mahfoud; Michael A Weber; Roland E Schmieder; Konstantinos Tsioufis; Stuart Pocock; Dimitris Konstantinidis; James W Choi; Cara East; David P Lee; Adrian Ma; Sebastian Ewen; Debbie L Cohen; Robert Wilensky; Chandan M Devireddy; Janice Lea; Axel Schmid; Joachim Weil; Tolga Agdirlioglu; Denise Reedus; Brian K Jefferson; David Reyes; Richard D'Souza; Andrew S P Sharp; Faisal Sharif; Martin Fahy; Vanessa DeBruin; Sidney A Cohen; Sandeep Brar; Raymond R Townsend
Journal:  Lancet       Date:  2020-03-29       Impact factor: 79.321

8.  Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial.

Authors:  David E Kandzari; Michael Böhm; Felix Mahfoud; Raymond R Townsend; Michael A Weber; Stuart Pocock; Konstantinos Tsioufis; Dimitrios Tousoulis; James W Choi; Cara East; Sandeep Brar; Sidney A Cohen; Martin Fahy; Garrett Pilcher; Kazuomi Kario
Journal:  Lancet       Date:  2018-05-23       Impact factor: 79.321

9.  A controlled trial of renal denervation for resistant hypertension.

Authors:  Deepak L Bhatt; David E Kandzari; William W O'Neill; Ralph D'Agostino; John M Flack; Barry T Katzen; Martin B Leon; Minglei Liu; Laura Mauri; Manuela Negoita; Sidney A Cohen; Suzanne Oparil; Krishna Rocha-Singh; Raymond R Townsend; George L Bakris
Journal:  N Engl J Med       Date:  2014-03-29       Impact factor: 91.245

10.  Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.

Authors:  Raymond R Townsend; Felix Mahfoud; David E Kandzari; Kazuomi Kario; Stuart Pocock; Michael A Weber; Sebastian Ewen; Konstantinos Tsioufis; Dimitrios Tousoulis; Andrew S P Sharp; Anthony F Watkinson; Roland E Schmieder; Axel Schmid; James W Choi; Cara East; Anthony Walton; Ingrid Hopper; Debbie L Cohen; Robert Wilensky; David P Lee; Adrian Ma; Chandan M Devireddy; Janice P Lea; Philipp C Lurz; Karl Fengler; Justin Davies; Neil Chapman; Sidney A Cohen; Vanessa DeBruin; Martin Fahy; Denise E Jones; Martin Rothman; Michael Böhm
Journal:  Lancet       Date:  2017-08-28       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.